TY - JOUR T1 - Promising efficacy of following a third dose of mRNA SARS-CoV-2 vaccination in patients treated with anti-CD20 antibody who failed 2-dose vaccination JF - medRxiv DO - 10.1101/2022.04.28.22274174 SP - 2022.04.28.22274174 AU - Yohei Funakoshi AU - Kimikazu Yakushijin AU - Goh Ohji AU - Wataru Hojo AU - Hironori Sakai AU - Marika Watanabe AU - Akihito Kitao AU - Yoshiharu Miyata AU - Yasuyuki Saito AU - Shinichiro Kawamoto AU - Katsuya Yamamoto AU - Mitsuhiro Ito AU - Taiji Koyama AU - Yoshinori Imamura AU - Naomi Kiyota AU - Hiroshi Matsuoka AU - Yasuko Mori AU - Hironobu Minami Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/01/2022.04.28.22274174.abstract N2 - Anti-CD20 antibodies react with CD20 expressed not only on malignant B cells but also on normal B cells. It has been reported that patients treated with anti-CD20 antibodies had an insufficient response to two-dose mRNA SARS-CoV-2 vaccination. To investigate the efficacy of a third dose in these patients, we investigated serum IgG antibody titers for S1 protein after third vaccination in 22 patients treated with anti-CD20 antibody who failed two-dose vaccination. Results showed that overall, 50% of patients seroconverted. Although no patient who received the third dose within 1 year of the last anti-CD20 antibody administration showed an increase in S1 antibody titer, 69% of patients who received the third dose more than 1 year after the last anti-CD20 antibody administration seroconverted. Our data show that a third dose of vaccination is effective in improving seroconversion rate in patients treated with anti-CD20 antibody who failed standard two-dose vaccination.Competing Interest StatementKYak has received research grants and honoraria from Chugai Pharmaceutical. WH and HS are employed by Cellspect Co., Ltd. NK has received grants from Roche Phamaceuticals. HM has received research grants and honoraria from Chugai Pharmaceutical. The other authors declare no potential conflicts of interest.Funding StatementDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of MedicineAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by Kobe University Hospital Ethics Committee (No. B2056714, 1481), and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent to participate.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -